← Leaderboards
Nicholas P Restifo
Clinical Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Clinical Sciences
Same institution · by research overlap
- David L Bartlett$7,205,000
- Patrick Hwu$17,535,407
- Larry W Kwak$10,852,773
- Steven A Rosenberg$0
- Jay A Berzofsky$0
Others in their field
Top investigators on “Tumor Antigens”
- William R Green · Dartmouth College$32,738,211
- John H Sampson · Duke University$30,849,602
- Catherine Ju-Ying Wu · Broad Institute, Inc.$30,485,072
- Elizabeth Marion Jaffee · Johns Hopkins University$26,862,085
- Ian M Thompson · University Of Texas Hlth Sci Ctr San Ant$24,066,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
Research focus
Tumor AntigensMelanomaNeoplasm /Cancer ImmunotherapyNeoplastic CellT LymphocyteVaccine DevelopmentNeoplasm /Cancer ImmunologyLaboratory MouseInterleukin 2Neoplasm /Cancer VaccineAntigen PresentationVector VaccineBiotechnologyHuman SubjectGenetically Modified AnimalsPatient Oriented ResearchHost Neoplasm InteractionRecombinant ProteinsSynthetic PeptideDisease /Disorder ModelImmunomodulatorsBackAutomobile DrivingAntibodies
Grant awards (9)
Building on the success of the adoptive immunotherapy of cancer$1,677,370
Z01 · FY2008 · CA · contact PI
Building on the success of the adoptive immunotherapy of cancer$4,687,435
Z01 · FY2007 · CA · contact PI
Building on the success of the adoptive immunotherapy of$0
Z01 · FY2006 · BC · contact PI
Molecular Approaches to the Development of Novel Tumor$0
Z01 · FY2005 · SC
Development of Novel Tumor Immunotherapies$0
Z01 · FY2004 · SC
Molecular Approaches to the Development of Novel Tumor I$0
Z01 · FY2003 · SC
Molecular Approaches to the Development of Novel Tumor I$0
Z01 · FY2002 · SC
Molecular Approaches--Develop. of Tumor Immunotherapies$0
Z01 · FY2001 · SC
Recombinant and Synthetic Anti-Cancer Vaccines$0
Z01 · FY2000 · SC